The Effect of HIV-Related Immunosuppression on the Risk of Tuberculosis Transmission to Household Contacts
Huang CC, Tchetgen ET, Becerra MC, Cohen T, Hughes KC, Zhang Z, Calderon R, Yataco R, Contreras C, Galea J, Lecca L, Murray M. The Effect of HIV-Related Immunosuppression on the Risk of Tuberculosis Transmission to Household Contacts. Clinical Infectious Diseases 2013, 58: 765-774. PMID: 24368620, PMCID: PMC3935504, DOI: 10.1093/cid/cit948.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusHousehold contactsIndex patientsCD4 countTuberculosis patientsTuberculosis transmissionHIV-negative tuberculosis patientsHIV-negative patientsHIV-positive patientsDrug-sensitive tuberculosisTuberculin skin testingTuberculosis infection statusRisk of infectionCoinfected PatientsActive tuberculosisTuberculosis infectionHIV statusSkin testingImmunodeficiency virusRisk factorsRelative riskPatientsTuberculosisInfection statusInfectionHealth benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models.
Eaton JW, Menzies NA, Stover J, Cambiano V, Chindelevitch L, Cori A, Hontelez JA, Humair S, Kerr CC, Klein DJ, Mishra S, Mitchell KM, Nichols BE, Vickerman P, Bakker R, Bärnighausen T, Bershteyn A, Bloom DE, Boily MC, Chang ST, Cohen T, Dodd PJ, Fraser C, Gopalappa C, Lundgren J, Martin NK, Mikkelsen E, Mountain E, Pham QD, Pickles M, Phillips A, Platt L, Pretorius C, Prudden HJ, Salomon JA, van de Vijver DA, de Vlas SJ, Wagner BG, White RG, Wilson DP, Zhang L, Blandford J, Meyer-Rath G, Remme M, Revill P, Sangrujee N, Terris-Prestholt F, Doherty M, Shaffer N, Easterbrook PJ, Hirnschall G, Hallett TB. Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models. The Lancet Global Health 2013, 2: e23-34. PMID: 25104632, DOI: 10.1016/s2214-109x(13)70172-4.Peer-Reviewed Original ResearchConceptsHIV-positive adultsAdult antiretroviral therapyAntiretroviral therapyCD4 countTreatment coveragePotential health benefitsConcentrated epidemicsDALY avertedHealth benefitsEligibility criteriaExpansion of eligibilityEarlier eligibilityCD4 count thresholdHealth system perspectiveHead gross domestic productMiddle-income settingsGeneral populationHealth outcomesKey populationsTherapyHealth interventionsHealth budgetIncremental costMelinda Gates FoundationEligibility